Literature DB >> 22450048

M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation.

Shangtong Jiang1, Yan Wang, Qilin Ma, Aina Zhou, Xian Zhang, Yun-wu Zhang.   

Abstract

A prime culprit in the pathogenesis of Alzheimer's disease (AD) is overproduction/aggregation of β-amyloid (Aβ), which is derived from β-Amyloid Precursor Protein through sequential cleavages by β-site APP cleaving protein 1 (BACE1) and γ-secretase. The level/activity of BACE1 is elevated in sporadic AD and identification of proteins that affect BACE1 is important in AD research. Here we found that M1 Muscarinic acetylcholine receptor (M1 mAChR), an important G protein-coupled receptor involved in cholinergic neuronal activity, can interact with BACE1 and mediate its proteosomal degradation. Moreover, overexpression and downregulation of M1 mAChR can decrease and increase the levels of BACE1, as well as the generation of Aβ, respectively. These findings point to a novel coupling of BACE1 and M1 mAChR in AD and possibly schizophrenia.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450048     DOI: 10.1016/j.neulet.2012.03.026

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.

Authors:  Bruce J Melancon; James C Tarr; Joseph D Panarese; Michael R Wood; Craig W Lindsley
Journal:  Drug Discov Today       Date:  2013-09-17       Impact factor: 7.851

2.  A gender dimorphism in up-regulation of BACE1 gene expression in schizophrenia.

Authors:  Nafiseh Nafisi-Far; Soudeh Ghafouri-Fard; Akram Sadat Tabatabaei Panah; Arezou Sayad; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2018-03-03       Impact factor: 3.584

Review 3.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

4.  Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Authors:  James C Tarr; Mark L Turlington; Paul R Reid; Thomas J Utley; Douglas J Sheffler; Hyekyung P Cho; Rebecca Klar; Tristano Pancani; Michael T Klein; Thomas M Bridges; Ryan D Morrison; Anna L Blobaum; Zixui Xiang; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Michael R Wood; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2012-07-18       Impact factor: 4.418

5.  Noradrenergic sympathetic sprouting and cholinergic reinnervation maintains non-amyloidogenic processing of AβPP.

Authors:  Amy R Nelson; Krystyna Kolasa; Lori L McMahon
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review.

Authors:  Kristy A Carpenter; Xudong Huang
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 7.  Mechanisms governing the reactivation-dependent destabilization of memories and their role in extinction.

Authors:  Charlotte R Flavell; Elliot A Lambert; Boyer D Winters; Timothy W Bredy
Journal:  Front Behav Neurosci       Date:  2013-12-26       Impact factor: 3.558

Review 8.  G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs.

Authors:  Juan Zhao; Yulin Deng; Zhaotan Jiang; Hong Qing
Journal:  Front Aging Neurosci       Date:  2016-03-24       Impact factor: 5.750

9.  Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Klaudia Chmielewska; Iwona Inkielewicz-Stepniak
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.